Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Fig. 5

XPO1 inhibitor KPT-335 induces G0/G1 phase cell cycle arrest by activating P53 function. A KPT-335 induced G0/G1 phase cell cycle arrest in SH-SY5Y. B baseline of P53, P27, P21 in SK-N-BE(2) and SH-SY5Y. C Relative growth of SK-N-BE(2) and SH-SY5Y after RG7388 treatment. D Knockdown of P53 attenuated inhibition effects of KPT-335 in SH-SY5Y. E P53, P27, P21 expression levels detected by western blotting after KPT-335 treatment. Data presented as mean ± SD (n = 3). * P < 0.05

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us